From the Journals

PBC linked to low BMD, increased risk of osteoporosis


 

FROM CLINICAL RHEUMATOLOGY

Patients with primary biliary cholangitis (PBC) have lower lumbar spine and hip bone mineral density (BMD) and are at an increased risk of osteoporosis and fracture, according to Junyu Fan, MD, and associates.

In a meta-analysis of 210 potentially relevant articles, only 8 met the study’s criteria. Of those, five studies were pooled and the overall relationship between PBC and osteoporosis risk was assessed. Results found a significant association between PBC (n = 504) and the prevalence of osteoporosis (P = .01), compared with the control group (n = 2,052).

©eranicle/Thinkstock
Five studies also were pooled to investigate the association between PBC and lumbar spine BMD, and two studies were used to evaluate the association between PBC and hip BMD. The results showed BMD of lumbar spine was considerably lower in the PBC patients (n = 572) than in controls (n = 886; P = .0002). Hip BMD was lower in the PBC patients (n = 209), compared with the controls (n = 242; P = .002). Lumbar spine T score was significantly lower in the PBC patients (n = 68) than in the controls (n = 99; P less than .00001).

The study additionally examined possible connection between PBC and bone fractures; more fracture events were reported in PBC patients (n = 929) than in controls (n = 8,699; P less than .00001). It is noted that there was no publication bias (P = .476).

“Further clinical management, follow-up, and surveillance issues should be addressed with caution,” researchers concluded. “Given the limited number of studies included, more high-quality studies will be required to determine the mechanisms underpinning the relationship between PBC and osteoporosis risk.”

Find the full study in Clinical Rheumatology (2017. doi: 10.1007/s10067-017-3844-x).

Recommended Reading

Worsening osteoporosis care for RA patients shows need for action
MDedge Rheumatology
Study finds low risk for jaw osteonecrosis with denosumab for postmenopausal osteoporosis
MDedge Rheumatology
Reduced fracture risk maintained in abaloparatide extension study
MDedge Rheumatology
Incidental hip CT scans could serve as osteoporosis screen
MDedge Rheumatology
PBC linked to increased risk of bone fracture
MDedge Rheumatology
Preferred osteoporosis treatment order with teriparatide, denosumab reaffirmed
MDedge Rheumatology
Teriparatide reduces fractures over risedronate in all subgroups with osteoporosis
MDedge Rheumatology
Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems
MDedge Rheumatology
ACP osteoporosis treatment guideline debated
MDedge Rheumatology
Gap in osteoporosis diagnosis and treatment stirs concern
MDedge Rheumatology